Re-Imagining Targeted therapy with CAM-V™ antibodies
CAM-V™ antibodies offer unique advantageous properties to potentially transform antibody therapy for patients fighting cancer
Sauvie’s initial program is a multi-specific construct of CAM-V™ antibodies to activate immune cells by binding to a potent activating antigen (receptor) CD16a and targeting cancer cells
PIPELINE
| Programs | Mid Discovery | Pre-Clinical | Optimization | IND Submission |
|---|---|---|---|---|
|
SV-0400 (CD16a:HER2+) |
 |
 |
 |
 |
|
Program 2 (CD16a:Target 2) |
|
 |
|
|
|
Program 3 (CD16a:Target 3) |
|
|
|
|
|
Program 4 |
|
|
|
|
|
Program 5 |
|
|
|
|
